Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 13/20 | 0.46 |
| ▸ | DRD4 | P21917 | 12/20 | 0.46 |
| ▸ | GFER | P55789 | 3/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | RAD52 | P43351 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | CASP6 | P55212 | 1/20 | 0.42 |
| ▸ | HTR7 | P34969 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.40 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.40 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4822865 | 0.85 | MAPT (0.57) | DRD2GFERMAPTSMN1; SMN2KMT2A | |
| SCHEMBL4863257 | 0.82 | DRD2 (0.65) | DRD2DRD4GFERKDM4EGAA | |
| SCHEMBL16824829 | 0.80 | GFER (0.53) | GFERKDM4EGAAMAPTRAD52 | |
| SCHEMBL24257354 | 0.78 | DRD2 (0.66) | DRD2DRD4 | |
| SCHEMBL31333719 | 0.78 | MEN1 (0.41) | GFERKDM4EGAAMAPTRAD52 | |
| SCHEMBL2880975 | 0.76 | KMT2A (0.54) | DRD2DRD4GFERKDM4EGAA | |
| SCHEMBL30981429 | 0.75 | KCNA3 (0.54) | DRD2GFERKDM4EGAAMAPT | |
| SCHEMBL4823574 | 0.75 | ALDH1A1 (0.55) | DRD2DRD4GFERMAPTSMN1; SMN2 | |
| SCHEMBL2876290 | 0.74 | GFER (0.51) | DRD2DRD4GFERKDM4EGAA | |
| SCHEMBL30965804 | 0.73 | DRD2 (0.43) | DRD2DRD4GFERKDM4EGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7442698-B2 | Substituted heterocyclic compounds and methods of use | AMGEN INC. (US) | 2008-10-28 | — | — | US | disclosed |
| US-20050107374-A1 | Substituted heterocyclic compounds and methods of use | AMGEN INC. | 2005-05-19 | — | — | US | disclosed |
| US-20050026914-A1 | Substituted heterocyclic compounds and methods of use | AMGEN INC. | 2005-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050026914-A1 | Substituted heterocyclic compounds and methods of use | NFATC1, ICOS, BET1 | DRD2 4369/4885DRD4 3050/4885GFER 2132/4885 |
| US-20050107374-A1 | Substituted heterocyclic compounds and methods of use | ICOS, CD4, HLA-DRB1 | DRD2 4675/4885DRD4 3634/4885GFER 1514/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.